Merck Receives FDA Approval for Keytruda Plus Chemotherapy as First-Line Treatment for Endometrial Cancer

Merck today announced that the FDA has approved Keytruda (pembrolizumab) in combination with carboplatin and paclitaxel, followed by Keytruda as a single agent, for the first-line treatment of advanced or recurrent endometrial carcinoma. The approval was based on results from the KEYNOTE-868/NRG-GY018 trial.